Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting
Listen to this expert overview of the most interesting findings related to the clinical use of bispecific antibody therapy for relapsed/refractory multiple myeloma that were presented at the 2024 annual American Society of Hematology meeting.
Decera Clinical Education Oncology Podcast · Shaji K. Kumar MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Shaji K. Kumar, MD, reviews key data on bispecific antibodies used to treat patients with relapsed/refractory multiple myeloma recently presented at the 2024 annual American Society of Hematology meeting, including:
- Early results with teclistamab combined with anti-CD38 therapy
- Real-world data with teclistamab including its use after other BCMA-targeted therapies
- Talquetamab as bridging therapy to BCMA-targeted CAR T-cell therapy
- Evaluation of prophylactic tocilizumab for cytokine-release syndrome associated with bispecific antibody therapy
Presenter:
Shaji K. Kumar, MD
Mark and Judy Mullins Professor of Hematologic Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Associate Chair for Research, Department of Medicine
Mayo Clinic
Rochester, Minnesota
Link to full program:
https://bit.ly/40bjFCZ
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.